drugset / Trial / NCT06736769
Ketamine Effects on Learning In Eating Disorders
Phase 2
Enrolling by invitation
20 enrolled
Amanda Downey, MD
National Center for Advancing Translational Sciences (NCATS) · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single site, single dose clinical trial of intravenous (IV) ketamine for medically hospitalized adolescents and young adults with anorexia nervosa or atypical anorexia nervosa. Eating disorder symptoms will be measured pre- and post-ketamine infusion. Investigators hypothesize that ketamine will increase cognitive flexibility, making medical hospitalizations less distressing by improving the ability to learn new, positive associations with food.
Timeline
- Start
- 2025-06-05
- Primary completion
- 2027-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketamine | Small molecule | 0.5 mg/kg | Intravenous |